Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment

Inclusion Criteria

All participants

• In the opinion of the investigator or subinvestigator, the participant is capable of understanding and complying with protocol requirements.
• Signs and dates a written, informed consent form prior to the initiation of any study procedures.
• Is either male or female and aged 20 to 85 years, inclusive, at the time of informed consent.
• Weighs at least 45 kilogram (kg) for males and 40 kg for females and have a body mass index (BMI) of less than ( =) 90 milliliter per minute per 1.73 square meter (mL/min/1.73 m^2) at screening.
• Based on the participant's medical history, clinical laboratory values, and physical examination findings, the investigator or subinvestigator judges the participant to be in good health (hypertension, type 2 diabetes, and hypercholesteremia or dyslipidemia are controlled, if present).
• Is within +/-10 years of the mean age and +/-20 percent (%) of the mean weight for the 24 participants with renal impairment and 12 participants with hepatic impairment administered the study drug.

Participants with renal impairment (Cohorts 2R, 3R, 4R, 5R)

• Falls into any of the following categories:
• With mild renal impairment (Cohort 2R): eGFR >=60 mL/min/1.73 m^2 and =30 mL/min/1.73 m^2 and 2.0 times higher than the upper limit of normal at screening.
• Has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antigen/antibody, or serological reactions for syphilis at screening.

Participants with renal impairment (Cohorts 2R, 3R, 4R, 5R)

• Has uncontrolled, clinically significant hepatic, neurologic, cardiovascular, blood, pulmonary, metabolic, gastrointestinal, urologic or endocrine disease, immune disease, infection or other abnormality, which may impact the ability of the participant to participate or potentially confound the study results.
• Sitting systolic blood pressure is 2.0 times higher than the upper limit of normal at screening.
• Has a positive test result for HBsAg, HCV antibody, HIV antigen/antibody, or serological reactions for syphilis at screening.

Participants with hepatic impairment (Cohorts 2H, 3H)

• Has uncontrolled, clinically significant renal, neurologic, cardiovascular, blood, pulmonary, metabolic, gastrointestinal, urologic or endocrine disease, immune disease, infection or other abnormality, which may impact the ability of the participant to participate or potentially confound the study results.
• Has ascites requiring invasive treatment.
• Systolic blood pressure is <80 mmHg at screening, in the pretreatment examination, or in the examination prior to the start of study drug administration and has repeated instances of the findings listed below, suggesting the presence of hypotension:
• Dizziness postural, facial pallor, cold sweats.
• eGFR is <60 mL/min/1.73 m^2 at screening.
• Has a positive test result for HIV antigen/antibody or the participant has a positive test result for serological reactions for syphilis and syphilis is judged not to have been cured at screening.